Thus, Epac2A seems to play a role in insulin secretion induced by the combination of an incretin and SU, especially in a model of diet-induced obesity, and may provide an explanation for the SU-dependent difference in the incidence rate of hypoglycemia observed in combination therapies. This evidence concerns the gene GCG and obesity disorder.